Oramed Pharmaceuticals Board Changes Announced
Ticker: ORMP · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.012 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-of-directors, management-change, filing
TL;DR
Oramed's board sees a new director, Dr. Kidron, while Mr. Kolber steps down.
AI Summary
Oramed Pharmaceuticals Inc. announced on June 6, 2024, a change in its board of directors. Specifically, Dr. Miriam Kidron has been appointed as a new director, and Mr. Jonathan Kolber has resigned from the board. The company also disclosed details regarding compensatory arrangements for its officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty regarding future strategic direction and management stability.
Key Players & Entities
- Oramed Pharmaceuticals Inc. (company) — Registrant
- Dr. Miriam Kidron (person) — Newly appointed director
- Mr. Jonathan Kolber (person) — Resigned director
- June 6, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new director to Oramed Pharmaceuticals' board?
Dr. Miriam Kidron has been appointed as a new director.
Who has resigned from the Oramed Pharmaceuticals board of directors?
Mr. Jonathan Kolber has resigned from the board.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 6, 2024.
What is the Commission File Number for Oramed Pharmaceuticals Inc.?
The Commission File Number is 001-35813.
What other information is disclosed in this filing besides director changes?
The filing also discloses details regarding compensatory arrangements of certain officers.
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2024-06-10 17:28:11
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Tel
Filing Documents
- ea0207486-8k_oramed.htm (8-K) — 32KB
- 0001213900-24-051355.txt ( ) — 202KB
- ormp-20240606.xsd (EX-101.SCH) — 3KB
- ormp-20240606_lab.xml (EX-101.LAB) — 33KB
- ormp-20240606_pre.xml (EX-101.PRE) — 22KB
- ea0207486-8k_oramed_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO June 10, 2024 2